146 related articles for article (PubMed ID: 8107652)
1. Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphoma.
Ozer H; Anderson JR; Peterson BA; Budman DR; Cooper MR; Kennedy BJ; Silver RT; Henderson ES; Duggan DB; Barcos M
Med Pediatr Oncol; 1994; 22(4):228-35. PubMed ID: 8107652
[TBL] [Abstract][Full Text] [Related]
2. Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma.
Ozer H; Anderson JR; Peterson BA; Budman DR; Henderson ES; Bloomfield CD; Gottlieb A
Invest New Drugs; 1987; 5 Suppl():S27-33. PubMed ID: 3298131
[TBL] [Abstract][Full Text] [Related]
3. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki D; Sklar J; Barcos M; Peterson BA
Leuk Lymphoma; 2001; 42(6):1255-64. PubMed ID: 11911406
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
Solal-Celigny P; Lepage E; Brousse N; Reyes F; Haioun C; Leporrier M; Peuchmaur M; Bosly A; Parlier Y; Brice P
N Engl J Med; 1993 Nov; 329(22):1608-14. PubMed ID: 8232429
[TBL] [Abstract][Full Text] [Related]
5. Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
Smith SM; Johnson J; Cheson BD; Canellos G; Petroni G; Oken M; Duggan D; Hurd D; Gockerman JP; Parker B; Prchal J; Peterson BA; ;
Leuk Lymphoma; 2009 Oct; 50(10):1606-17. PubMed ID: 19626540
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Enschede SH; Porter C; Venugopal P; Gregory SA
Clin Adv Hematol Oncol; 2004 Apr; 2(4):229-33. PubMed ID: 16163187
[TBL] [Abstract][Full Text] [Related]
7. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
8. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.
Peterson BA; Petroni GR; Frizzera G; Barcos M; Bloomfield CD; Nissen NI; Hurd DD; Henderson ES; Sartiano GP; Johnson JL; Holland JF; Gottlieb AJ
J Clin Oncol; 2003 Jan; 21(1):5-15. PubMed ID: 12506163
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S;
Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633
[TBL] [Abstract][Full Text] [Related]
10. Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: an interim report of a randomized study. Non-Hodgkin's Lymphoma Cooperative Study Group.
Chisesi T; Congiu M; Contu A; Coser P; Moretti L; Porcellini A; Rancan L; Salvagno L; Santini G; Vinante O
Eur J Cancer; 1991; 27 Suppl 4():S31-3. PubMed ID: 1799472
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study.
Moore DH; Valea F; Walton LA; Soper J; Clarke-Pearson D; Fowler WC
Gynecol Oncol; 1995 Nov; 59(2):267-72. PubMed ID: 7590485
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
14. alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone.
Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R; van de Loo J
Eur J Cancer; 1991; 27 Suppl 4():S37-9. PubMed ID: 1799474
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress.
Price CG; Rohatiner AZ; Steward W; Deakin D; Bailey N; Norton A; Blackledge G; Crowther D; Lister TA
Ann Oncol; 1991 Feb; 2 Suppl 2():141-5. PubMed ID: 2049311
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
Santini G; Chisesi T; Nati S; Porcellini A; Zoli V; Rizzoli V; Zupo S; Marino G; Rubagotti A; Polacco A; Spriano M; Vimercati R; Congiu AM; Ravetti JL; Aversa S; Candela M; Patti C
Leuk Lymphoma; 2004 Jun; 45(6):1141-7. PubMed ID: 15359993
[TBL] [Abstract][Full Text] [Related]
18. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
19. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa for the treatment of follicular lymphomas.
Hiddemann W; Griesinger F; Unterhalt M
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S13-8. PubMed ID: 9672770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
